VIDEO: Breast Cancer Clinical Trial Breakthroughs - Updates from ASCO 2025Editor’s Note: In 2025, the FDA approved Inluriyo™ (imlunestrant), an oral selective estrogen receptor degrader (SERD), for ER-positive, HER2-negative, ESR1-mutated, second-line advanced...reactionscomments
Addressing Breast Cancer Patients' Misconceptions on Palliative CareNavigating a cancer diagnosis is difficult for patients and their loved ones. Patients have to learn complex information to understand their condition...reactionscomments
HCPs: Test Your Treatment KnowledgeNavigating the complexities of breast cancer requires a deep understanding of evolving research and targeted therapies. Take our quiz to test your...reactionscomments
HCPs: Test What You Know About Symptom ManagementReady to test your knowledge on a critical aspect of patient care? This quiz will challenge your expertise in managing the diverse...reactionscomments
The Molecular Map: A Guide to Biomarker-Driven TherapyIn the past, a one-size-fits-all approach was often used for breast cancer treatment. Now, precision medicine is a revolutionary approach that tailors...reactionscomments
